Postmenopausal hormone therapy: Risks and benefits

Nature Reviews Endocrinology

Volumn 9, Issue 4, 2013, Pages 216-227

  Rozenberg, Serge ^a   Vandromme, Jean ^a   Antoine, Caroline ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALGESTONE; AROMATASE INHIBITOR; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DENOSUMAB; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GABAPENTIN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PARATHYROID HORMONE; PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN UPTAKE INHIBITOR; STRONTIUM RANELATE; TIBOLONE; TRIMEGESTONE; VITAMIN D;

BREAST CANCER; CANCER RISK; CANCER SURVIVOR; CEREBROVASCULAR ACCIDENT; COGNITION; COLORECTAL CANCER; DEMENTIA; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOMETRIUM CANCER; ESTROGEN DEFICIENCY; FOLLOW UP; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; ISCHEMIC HEART DISEASE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MENOPAUSAL SYNDROME; NONHUMAN; OSTEOPOROSIS; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; URINE INCONTINENCE; VAGINA ATROPHY; VENOUS THROMBOEMBOLISM;

ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; POSTMENOPAUSE; PROGESTINS; RISK ASSESSMENT;

EID: 84875421953     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2013.17     Document Type: Review

References (141)

1. Smith, D. C., Prentice, R., Thompson, D. J. & Herrmann, W. L. Association of exogenous estrogen and endometrial carcinoma. N. Engl. J. Med. 293, 1164-1167 (1975).
2. Hammond, C. B., Jelovsek, F. R., Lee, K. L., Creasman, W. T. & Parker, R. T. Effects of long-term estrogen replacement therapy. II. Neoplasia. Am. J. Obstet. Gynecol. 133, 537-547 (1979).
3. Lindsay, R., Hart, D. M., Forrest, C. & Baird, C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 2, 1151-1154 (1980).
4. Rozenberg, S., Vandromme, J., Kroll, M., Pastijn, A. & Degueldre, M. Osteoporosis prevention with sex hormone replacement therapy. Int. J. Fertil. Menopausal Stud. 39, 262-271 (1994).
5. Udoff, L., Langenberg, P. & Adashi, E. Y. Combined continuous hormone replacement therapy: a critical review. Obstet. Gynecol. 86, 306-316 (1995).
6. Pickar, J. H., Thorneycroft, I. & Whitehead, M. Effects of hormone replacement therapy on the endometrium and lipid parameters: a review of randomized clinical trials, 1985 to 1995. Am. J. Obstet. Gynecol. 178, 1087-1099 (1998).
7. Dören, M., Nilsson, J. A. & Johnell, O. Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis. Hum. Reprod. 18, 1737-1746 (2003).
8. Barrett-Connor, E. et al. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. Maturitas 27, 261-274 (1997).
9. Grodstein, F. et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. 133, 933-941 (2000).
10. Clarkson, T. B. & Appt, S. E. Controversies about HRT-lessons from monkey models. Maturitas 51, 64-74 (2005).
11. Sherwin, B. B. & Henry, J. F. Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: a critical review. Front. Neuroendocrinol. 29, 88-113 (2008).
12. Stefanick, M. L. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am. J. Med. 118 (Suppl. 12B), 64-73 (2005).
13. Hulley, S. et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280, 605-613 (1998).
14. Rossouw, J. E. Estrogens for prevention of coronary heart disease. Putting the brakes on the bandwagon. Circulation 94, 2982-2985 (1996).
15. Hulley, S. Estrogens should not be initiated for the secondary prevention of coronary artery disease: a debate. Can. J. Cardiol. 16 (Suppl. E), 10E-12E (2000).
16. Manson, J. E. et al. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 349, 523-534 (2003).
17. Solomon, C. G. & Dluhy, R. G. Rethinking postmenopausal hormone therapy. N. Engl. J. Med. 348, 579-580 (2003).
18. Ena, G. & Rozenberg, S. Issues to debate on the Women's Health Initiative (WHI) study. Prescription attitudes among Belgian gynaecologists after premature discontinuation of the WHI study. Hum. Reprod. 18, 2245-2248 (2003).
19. Bush, T. M. et al. How the Women's Health Initiative (WHI) influenced physicians' practice and attitudes. J. Gen. Intern. Med. 22, 1311-1316 (2007).
20. Gompel, A., Rozenberg, S., Barlow D. H. & EMAS board members. The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy. Maturitas 61, 227-232 (2008).
21. LaCroix, A. Z. et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305, 1305-1314 (2011).
22. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 19, 257-271 (2012).
23. Stuenkel, C. A. et al. A decade after the Women's Health Initiative-the experts do agree. J. Clin. Endocrinol. Metab. 97, 2617-2618 (2012).
24. Notelovitz, M. Clinical opinion: the biologic and pharmacologic principles of estrogen therapy for symptomatic menopause. MedGenMed. 8, 85 (2006).
25. Nath, A. & Sitruk-Ware, R. Different cardiovascular effects of progestins according to structure and activity. Climacteric 12 (Suppl. 1), 96-101 (2009).
26. Palacios, S. et al. EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis. Maturitas 71, 194-198 (2012).
27. Maclennan, A. H., Broadbent, J. L., Lester, S. & Moore, V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD002978. http://dx.doi.org/10.1002/14651858.CD002978.pub2.
28. Formoso, G. et al. Short and long term effects of tibolone in postmenopausal women. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD008536. http://dx.doi.org/10.1002/14651858.CD008536.pub2.
29. Nelson, H. D. et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 295, 2057-2071 (2006).
30. Antoine, C., Liebens, F., Carly, B., Pastijn, A. & Rozenberg, S. Safety of alternative treatments for menopausal symptoms after breast cancer: a qualitative systematic review. Climacteric 10, 23-26 (2007).
31. Loprinzi, C. L. et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J. Clin. Oncol. 27, 2831-2837 (2009).
32. Toulis, K. A., Tzellos, T., Kouvelas, D. & Goulis, D. G. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. Clin. Ther. 31, 221-235 (2009).
33. Rada, G. et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database of Systematic Reviews, Issue 9. Art. No.: CD004923. http://dx.doi.org/10.1002/14651858.CD004923. pub2.
34. Daley, A., Stokes-Lampard, H. & Macarthur, C. Exercise for vasomotor menopausal symptoms. Cochrane Database of Systematic Reviews, Issue 5. Art. No.: CD006108. http://dx.doi.org/10.1002/14651858.CD006108.pub3.
35. Leach, M. J. & Moore, V. Black cohosh (Cimicifuga spp) for menopausal symptoms. Cochrane Database of Systematic Reviews, Issue 9. CD007244. http://dx.doi.org/10.1002/14651858.CD007244.pub2.
36. Eden, J. A. Phytoestrogens for menopausal symptoms: a review. Maturitas 72, 157-159 (2012).
37. Langer, R. D. Efficacy, safety, and tolerability of low-dose hormone therapy in managing menopausal symptoms. J. Am. Board Fam. Med. 22, 563-573 (2009).
38. Reginster, J. Y. et al. Effect of transdermal 17β-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause. Calcif. Tissue Int. 53, 13-16 (1993).
39. Wells, G. et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr. Rev. 23, 529-539 (2002).
40. Cummings, S. R. et al. The effects of tibolone in older postmenopausal women. N. Engl. J. Med. 359, 697-708 (2008).
41. Nelson, H. D., Walker, M., Zakher, B. & Mitchell, J. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U. S. Preventive Services Task Force recommendations. Ann. Intern. Med. 157, 104-113 (2012).
42. Cauley, J. et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290, 1729-1738 (2003).
43. Anderson, G. L. et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291, 1701-1712 (2004).
44. Santen, R. J. et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J. Clin. Endocrinol. Metab. 95 (Suppl. 1), S1-S66 (2010).
45. MacLean, C. et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann. Intern. Med. 148, 197-213 (2008).
46. Body, J. J. et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos. Int. 21, 1657-1680 (2010).
47. Anderson, G. L. et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 13, 476-486 (2012).
48. Nappi, R. E. & Kokot-Kierepa, M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 67, 233-238 (2010).
49. Lynch, C. Vaginal estrogen therapy for the treatment of atrophic vaginitis. J. Womens Health (Larchmt) 18, 1595-1606 (2009).
50. Bachmann, G. A., Komi J. O. & Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 17, 480-486 (2010).
51. Cody, J. D., Jacobs, M. L, Richardson, K., Moehrer, B. & Hextall, A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database of Systematic Reviews, Issue 10. Art. No.: CD001405. http://dx.doi.org/10.1002/14651858.CD001405. pub3.
52. Ismail, S. I., Bain, C. & Hagen, S. Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women. Cochrane Database of Systematic Reviews, Issue 9. Art. No.: CD007063. http://dx.doi.org/10.1002/ 14651858.CD007063.pub2.
53. Col, N. F. et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 277, 1140-1147 (1997).
54. Sullivan, J. M., El-Zeky, F., Vander Zwaag, R. & Ramanathan, K. B. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am. J. Cardiol. 79, 847-850 (1997).
55. Grodstein, F. & Stampfer, M. J. Estrogen for women at varying risk of coronary disease. Maturitas 30, 19-26 (1998).
56. Marjoribanks, J., Farquhar, C., Roberts, H. & Lethaby, A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews Issue 7. Art. No.: CD004143. http://dx.doi.org/10.1002/ 14651858.CD004143.pub4.
57. Hodis, H. N. et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 135, 939-953 (2001).
58. Hodis, H. N. et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N. Engl. J. Med. 349, 535-545 (2003).
59. Manson, J. E. et al. Estrogen therapy and coronary-artery calcification. N. Engl. J. Med. 356, 2591-2602 (2007).
60. Mendelsohn, M. E. & Karas, R. H. HRT and the young at heart. N. Engl. J. Med. 356, 2639-2641 (2007).
61. Hernán, M. A. et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology 19, 766-779 (2008).
62. Hodis, H. N. & Mack, W. J. A "window of opportunity:" the reduction of coronary heart disease and total mortality with menopausal therapies is age-and time-dependent. Brain Res. 1379, 244-252 (2011).
63. Tuomikoski, P., Ylikorkala, O. & Mikkola T. S. Menopausal hot flushes and vascular health. Ann. Med. 43, 283-291 (2011).
64. Schierbeck, L. L. et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 345, e6409 (2012).
65. Lobo, R. A. & Clarkson, T. B. Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women: a hypothetical explanation. Menopause 18, 237-240 (2011).
66. Bath, P. M. & Gray, L. J. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 330, 342 (2005).
67. Sare, G. M., Gray, L. J. & Bath, P. M. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur. Heart J. 29, 2031-2041 (2008).
68. Grodstein, F., Manson, J. E., Stampfer, M. J. & Rexrode, K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch. Intern. Med. 168, 861-866 (2008).
69. Renoux, C., Dell'aniello, S., Garbe, E. & Suissa, S. Hormone replacement therapy use and the risk of stroke. Maturitas 61, 305-309 (2008).
70. Sweetland, S. et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J. Thromb. Haemost. http://dx.doi.org/10.1111/j.1538-7836. 2012.04919.x.
71. Canonico, M., Plu-Bureau, G., Lowe, G. D. & Scarabin, P. Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 336, 1227-1231 (2008).
72. Olié, V., Canonico, M. & Scarabin, P. Y. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr. Opin. Hematol. 17, 457-463 (2010).
73. Tremollieres, F. et al. EMAS position statement: managing menopausal women with a personal or family history of VTE. Maturitas 69, 195-198 (2011).
74. Anderson, G. L. et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 55, 103-115 (2006).
75. Chlebowski, R. T. et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304, 1684-1692 (2010).
76. Fournier, A., Mesrine, S., Boutron-Ruault, M. C. & Clavel-Chapelon, F. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J. Clin. Oncol. 27, 5138-5143 (2009).
77. Lyytinen, H., Pukkala, E. & Ylikorkala, O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet. Gynecol. 113, 65-73 (2009).
78. Prentice, R. L. et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am. J. Epidemiol. 167, 1207-1216 (2008).
79. Prentice, R. L. et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am. J. Epidemiol. 167, 1407-1415 (2008).
80. Beral, V., Reeves, G., Bull, D., Green J. & Million Women Study Collaborators. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J. Natl Cancer Inst. 103, 296-305 (2011).
81. Crandall, C. J. et al. Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone Women's Health Initiative clinical trials. Breast Cancer Res. Treat. 132, 275-285 (2012).
82. Couto, E. et al. Hormone therapy use and mammographic density in postmenopausal Norwegian women. Breast Cancer Res. Treat. 132, 297-305 (2012).
83. Chlebowski, R. T. et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N. Engl. J. Med. 360, 573-587 (2009).
84. Grady, D., Gebretsadik, T., Kerlikowske, K., Ernster, V. & Petitti, D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet. Gynecol. 85, 304-313 (1995).
85. Furness, S., Roberts, H., Marjoribanks, J. & Lethaby, A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database of Systematic Reviews, Issue 8. Art. No.: CD000402. http://dx.doi.org/10.1002/14651858.CD000402.pub4.
86. Skouby, S. O. et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri-and postmenopausal hormone replacement therapy. Maturitas 51, 8-14 (2005).
87. Anderson, G. L. et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 290, 1739-1748 (2003).
88. Greiser, C. M., Greiser, E. M. & Dören, M. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum. Reprod. Update 13, 453-463 (2007).
89. Pearce, C. L., Chung, K., Pike, M. C. & Wu, A. H. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 115, 531-539 (2009).
90. Mørch, L. S., Løkkegaard, E., Andreasen, A. H., Kjaer, S. K. & Lidegaard, O. Hormone therapy and different ovarian cancers: a national cohort study. Am. J. Epidemiol. 175, 1234-1242 (2012).
91. National Cancer Institute. Seer Stats Fact Sheet: Ovary [online], http://seer.cancer.gov/statfacts/html/ovary.html#risk (2012).
92. Grodstein, F., Newcomb, P. A. & Stampfer, M. J. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am. J. Med. 106, 574-582 (1999).
93. Simon, M. S. et al. Estrogen plus progestin and colorectal cancer incidence and mortality. J. Clin. Oncol. 30, 3983-3990 (2012).
94. Chlebowski, R. T. et al. Lung cancer among postmenopausal women treated with estrogen alone in the Women's Health Initiative randomized trial. J. Natl Cancer Inst. 102, 1413-1421 (2010).
95. Chlebowski, R. T. et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 374, 1243-1251 (2009).
96. Antoine, C. et al. Safety of hormone therapy after breast cancer: a qualitative systematic review. Hum. Reprod. 22, 616-622 (2007).
97. von Schoultz, E., Rutqvist L. E. & Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J. Natl Cancer Inst. 97, 533-535 (2005).
98. Holmberg, L., Anderson, H. & HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet 363, 453-455 (2004).
99. Holmberg, L. et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J. Natl Cancer Inst. 100, 475-482 (2008).
100. Kenemans, P. et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol. 10, 135-146 (2009).
101. Fahlén, M. et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur. J. Cancer 49, 52-59 (2013).
102. Antoine, C. et al. A survey among breast cancer survivors: treatment of the climacteric after breast cancer. Climacteric 11, 322-328 (2008).
103. Kendall, A., Dowsett, M., Folkerd, E. & Smith, I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann. Oncol. 17, 584-587 (2006).
104. Hickey, M. et al. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann. Oncol. 19, 1669-1680 (2008).
105. Bordeleau, L., Pritchard, K., Goodwin, P. & Loprinzi, C. Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clin. Ther. 29, 230-241 (2007).
106. Chapman, J. A. et al. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am. J. Obstet. Gynecol. 175, 1195-1200 (1996).
107. Suriano, K. A. et al. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet. Gynecol. 97, 555-560 (2001).
108. Barakat, R. R. et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 24, 587-592 (2006).
109. Rozenberg, S. & Vasquez, J. B. Estrogen replacement therapy in patients with endometrial cancer: prescription attitude of Belgian gynecologists. Maturitas 35, 125-128 (2000).
110. Maxwell, G. L. et al. Racial disparities in recurrence among patients with early-stage endometrial cancer: is recurrence increased in black patients who receive estrogen replacement therapy? Cancer 113, 1431-1437 (2008).
111. Biglia, N., Gadducci, A., Ponzone, R., Roagna, R. & Sismondi, P. Hormone replacement therapy in cancer survivors. Maturitas 48, 333-346 (2004).
112. Guidozzi, F. & Daponte, A. Estrogen replacement therapy for ovarian cancer survivors: a randomized controlled trial. Cancer 86, 1013-1018 (1999).
113. Ovarian Cancer Canada. Treatment and recovery, surgery [online], http://www.ovariancanada.org/KnowledgeAwareness/Treatment-And-Recovery/Surgery (2012).
114. Barrett-Connor, E. & Laughlin, G. A. Endogenous and exogenous estrogen, cognitive function, and dementia in postmenopausal women: evidence from epidemiologic studies and clinical trials. Semin. Reprod. Med. 27, 275-282 (2009).
115. Henderson, V. W. Aging, estrogens, and episodic memory in women. Cogn. Behav. Neurol. 22, 205-214 (2009).
116. Hogervorst, E. & Bandelow, S. Sex steroids to maintain cognitive function in women after the menopause: a meta-analyses of treatment trials. Maturitas 66, 56-71 (2010).
117. Silverman, D. H. et al. Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD. Psychoneuroendocrinology 36, 502-513 (2011).
118. Shao, H. et al. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology 79, 1846-1852 (2012).
119. Shumaker, S. A. et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291, 2947-2958 (2004).
120. Hays, J. et al. Effects of estrogen plus progestin on health-related quality of life. N. Engl. J. Med. 348, 1839-1854 (2003).
121. Brunner, R. L. et al. Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative randomized clinical trial. Arch. Intern. Med. 165, 1976-1986 (2005).
122. Nielsen, T. F., Ravn, P., Pitkin, J. & Christiansen, C. Pulsed estrogen therapy improves postmenopausal quality of life: a 2-year placebo-controlled study. Maturitas 53, 184-190 (2006).
123. Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002).
124. Cauley, J. A. et al. Estrogen replacement therapy and mortality among older women. The study of osteoporotic fractures. Arch. Intern. Med. 157, 2181-2187 (1997).
125. Paganini-Hill, A., Corrada, M. M. & Kawas, C. H. Increased longevity in older users of postmenopausal estrogen therapy: the Leisure World Cohort Study. Menopause 13, 12-18 (2006).
126. Ryan, J. et al. Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study. PLoS ONE 7, e34112 (2012).
127. Moyer, V. A & on behalf of the U.S. Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: U. S. Preventive Services Task Force Recommendation Statement. Ann. Intern. Med. 158, 47-54 (2013).
128. Shuster, L. T., Gostout, B. S., Grossardt, B. R. & Rocca, W. A. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int. 14, 111-116 (2008).
129. Vujovic, S. et al. EMAS position statement: managing women with premature ovarian failure. Maturitas 67, 91-93 (2010).
130. Sim, L. A. et al. Effect on bone health of estrogen preparations in premenopausal women with anorexia nervosa: a systematic review and meta-analyses. Int. J. Eat. Disord. 43, 218-225 (2010).
131. Kanis, J. A. et al. Development and use of FRAX in osteoporosis. Osteoporos. Int. 21 (Suppl. 2), S407-S413 (2010).
132. Rockhill, B., Spiegelman, D., Byrne, C., Hunter, D. J. & Colditz G. A. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J. Natl Cancer Inst. 93, 358-366 (2001).
133. Tyrer, J., Duffy, S. W. & Cuzick, J. A breast cancer prediction model incorporating familial and personal risk factors. Stat. Med. 23, 1111-1130 (2004).
134. Pencina, M. J., D'Agostino, R. B. Sr, Larson, M. G., Massaro, J. M. & Vasan, R. S. Predicting the 30-year risk of cardiovascular disease: the Framingham heart study. Circulation 119, 3078-3084 (2009).
135. Ridker, P. M., Buring, J. E., Rifai, N. & Cook, N. R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score. JAMA 297, 611-619 (2007).
136. Collins, G. S. & Altman, D. G. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ 340, c2442 (2010).
137. Perk, J. et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 33, 1635-1701 (2012).
138. Hippisley-Cox, J. & Coupland, C. A. Development and validation of a risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study. BMJ 343, d4656 (2011).
139. Billon-Galés, A. et al. Activation function 2 (AF2) of estrogen receptor-α is required for the atheroprotective action of estradiol but not to accelerate endothelial healing. Proc. Natl Acad. Sci. USA 108, 13311-13316 (2011).
140. Mackey, R. H. et al. Hormone therapy, estrogen metabolism, and risk of breast cancer in the Women's Health Initiative Hormone Therapy Trial. Cancer Epidemiol. Biomarkers Prev. 20, 2022-2032 (2012).
141. Huang, Y. et al. Exploring the interaction between SNP genotype and postmenopausal hormone therapy effects on stroke risk. Genome Med. 4, 57 (2012).